Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Paul Cornes, MD from the University Hospital Bristol NHS Foundation Trust, Bristol, UK takes us through the concept of batch variation in branded biologics, how it has been justified by regulators and trusted by doctors, and how the same principles and strict rules have been put in place to justify the manufacture of biosimilar drugs.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.